OAsIs is an early phase trial that tested three targeted drugs in people with mantle cell lymphoma. It included people with mantle cell lymphoma that had come back or not responded after previous treatment (relapsed or refractory mantle cell lymphoma) as well as people who had not been treated before. The trial aimed to find out if a combination of three targeted drugs is safe and works well.
The treatments in the trial were:
- Obinutuzumab, an antibody therapy that sticks to a protein called CD20 on lymphoma cells. It is given through a drip into a vein once a week for the first 3 weeks of treatment, and then gradually reducing to once every 8 weeks.
- Ibrutinib, a cell signal blocker that blocks a protein called BTK, which is part of a pathway that helps B lymphocytes stay alive. It is a taken as a tablet once a day.
- Venetoclax, which blocks a protein called BCL-2 that helps cancer cells stay alive. It is taken as a tablet once a day.
In total, 48 people took part in the trial.
After six cycles of treatment, lymphoma could no longer be detected on PET scans in:
- almost 9 out of every 10 people who had not been treated before
- around 7 out of every 10 people with relapsed or refractory mantle cell lymphoma.
The trial also found that after three cycles of treatment, lymphoma cells could no longer be detected in bone marrow or blood samples from:
- all of the people who had not been treated before
- 7 in every 10 people with relapsed or refractory mantle cell lymphoma.
It is important to remember that these results are from an early phase trial and more research is needed to confirm the role of this chemotherapy-free combination in mantle cell lymphoma.
To find out more about clinical trials for lymphoma, or to search for a trial that might be suitable for you, visit Lymphoma TrialsLink.
17 May 2021